ATE136940T1 - Diagnostische methode - Google Patents

Diagnostische methode

Info

Publication number
ATE136940T1
ATE136940T1 AT93916109T AT93916109T ATE136940T1 AT E136940 T1 ATE136940 T1 AT E136940T1 AT 93916109 T AT93916109 T AT 93916109T AT 93916109 T AT93916109 T AT 93916109T AT E136940 T1 ATE136940 T1 AT E136940T1
Authority
AT
Austria
Prior art keywords
pct
sec
diagnostic method
date
date apr
Prior art date
Application number
AT93916109T
Other languages
English (en)
Inventor
David Tarin
Yasuhiro Matsumura
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27266293&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE136940(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB929215498A external-priority patent/GB9215498D0/en
Priority claimed from GB929224386A external-priority patent/GB9224386D0/en
Priority claimed from GB929226165A external-priority patent/GB9226165D0/en
Application filed by Isis Innovation filed Critical Isis Innovation
Application granted granted Critical
Publication of ATE136940T1 publication Critical patent/ATE136940T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
AT93916109T 1992-07-21 1993-07-20 Diagnostische methode ATE136940T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929215498A GB9215498D0 (en) 1992-07-21 1992-07-21 Diagnostic method
GB929224386A GB9224386D0 (en) 1992-11-20 1992-11-20 Nucleic acid sequence
GB929226165A GB9226165D0 (en) 1992-12-16 1992-12-16 Nucleic acid sequence

Publications (1)

Publication Number Publication Date
ATE136940T1 true ATE136940T1 (de) 1996-05-15

Family

ID=27266293

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93916109T ATE136940T1 (de) 1992-07-21 1993-07-20 Diagnostische methode

Country Status (7)

Country Link
US (1) US5830646A (de)
EP (1) EP0651822B1 (de)
JP (1) JP2800850B2 (de)
AT (1) ATE136940T1 (de)
CA (1) CA2139410A1 (de)
DE (1) DE69302276T2 (de)
WO (1) WO1994002633A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2164728A1 (en) * 1993-06-22 1995-01-05 Helmut Ponta Processes for diagnosing and analysing tumours
GB9317139D0 (en) * 1993-08-18 1993-10-06 Miniser For Agriculture Fisher Method and test kits for detection of bacteriophage
DE4431297A1 (de) * 1994-09-02 1996-03-07 Boehringer Ingelheim Int Monoklonaler Antikörper gegen CD44v6
CA2195404A1 (en) * 1994-07-21 1996-02-08 David Tarin Diagnostic method and probe
DE19545472A1 (de) * 1995-12-06 1997-06-12 Boehringer Ingelheim Int Verfahren zur Diagnose und Therapie von Plattenepithelkarzinomen
DE19653607A1 (de) 1996-12-20 1998-06-25 Boehringer Ingelheim Int Verfahren zur Diagnose und Therapie von Hodgkin-Lymphomen
WO1999004036A1 (en) * 1997-07-14 1999-01-28 Isis Innovation Limited Cd44 based cancer detection
US20030170637A1 (en) * 2002-03-06 2003-09-11 Pirrung Michael C. Method of analyzing mRNA splice variants

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4014510A1 (de) * 1990-05-07 1991-11-14 Kernforschungsz Karlsruhe Variante cd44-oberflaechenproteine, diese kodierende c-dna-sequenzen, antikoerper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie
AU658370B2 (en) * 1990-07-13 1995-04-13 General Hospital Corporation, The CD53 cell surface antigen and use thereof

Also Published As

Publication number Publication date
WO1994002633A1 (en) 1994-02-03
CA2139410A1 (en) 1994-02-03
DE69302276D1 (de) 1996-05-23
JP2800850B2 (ja) 1998-09-21
US5830646A (en) 1998-11-03
EP0651822B1 (de) 1996-04-17
JPH08500731A (ja) 1996-01-30
EP0651822A1 (de) 1995-05-10
DE69302276T2 (de) 1996-09-19

Similar Documents

Publication Publication Date Title
Daly Anti‐bacterial effect of citric acid treatment of periodontally diseased root surfaces in vitro
DE69531457D1 (en) Sulfonamide
AU7635396A (en) Treatment and diagnosis of infections due to helicobacter pylori
GR3031488T3 (en) Laminin chains: diagnostic and therapeutic use
AU6173501A (en) Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
ATE189957T1 (de) Verwendung von nadph-oxidase-inhibitoren zur herstellung eines arzneimittels zur vorbeugung der arteriosklerose
AU2738195A (en) Tumor diagnosis and prognosis
DE3852275D1 (de) Ultraschallsonde für intravaskulären Katheter zur Behandlung intravaskulärer Verschlüsse.
EP0641204A4 (de) 17-ether und thioether von 4-aza-steroiden.
ATE226052T1 (de) Schutzhülle für eine sonde
DE69302276D1 (de) Diagnostische Methode
NO953770D0 (no) Analysemetode
AU629611B2 (en) Process for the determination, by means of free radicals, of the anti-oxidant properties of a living organism or a potentially agressive agent
DE69226775D1 (de) Dns-sequenzen von hpv42 papillomavirus :verwendungsmöglichkeit für diagnose
DE60122673D1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
DE69517191D1 (de) Wasserlösliche derivate epipodophyllotoxine, verfahren zu ihrer herstellung, ihre verwendung als medikament und ihre verwendung zur herstellung eines antikrebsmittels
Kozlovsky et al. Cell surface hydrophobicity of Actinobacillus actinomycetemcomitans Y4
DK0870036T3 (da) Syntetisk pattedyrs-alfa-N-acetylglucosaminidase og genetiske sekvenser kodende derfor
EP1064402A4 (de) Antisense modulierung von lfa-3
ATE240352T1 (de) Komplexverbindungen zur diagnose von gefässerkrankungen
Owen Improved in vitro determination of the viability of Taenia saginata embryos
DE59206718D1 (de) Verfahren zur diagnose von nicht-insulin-abhängigem diabetes mellitus
US3336204A (en) Inhibition of specific naphthylamide hydrolyzing enzymes (leucine aminopeptidase) with detoxified snake serum
ATE151816T1 (de) Nachweis synthetischer oligonucleotide extrahiert aus körperflüssigkeiten oder geweben:
RU94038422A (ru) Способ оценки эффективности лечения атопического дерматита у детей

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
RZN Patent revoked